As part of the deal, Boehringer is responsible for the global development and commercialization of the new inhibitors, while Hydra will receive an undisclosed upfront payment, additional research funding, as well as milestone payments and tiered royalty payments on future product sales.
Boehringer Ingelheim Research and Non-clinical Development senior corporate vice president of Dr Michel Pairet said: "This new collaboration agreement with Hydra Biosciences reflects the importance and value Boehringer Ingelheim places in developing strong research partnerships to discover new treatments for renal diseases and related disorders.
"We are very excited to be able to continue to work together with Hydra Biosciences. Renal diseases and disorders are of increasing importance to Boehringer Ingelheim as part of our CardioMetabolic Diseases Research area, and our dedicated renal disease research unit based in Ridgefield, CT, USA, is constantly expanding its network of partnerships in this field."
The collaboration is the second between the two firms, which are currently collaborating to research and develop small-molecule TRPC4/5 inhibitors to treat central nervous system (CNS) diseases and disorders.